Nexalin Technology announced that the United States Patent and Trademark Office has awarded U.S. Patent No. 17/337,653 relating to the company’s non-invasive, frequency-based deep brain stimulation device. The newly issued patent, entitled, “Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia,” covers the method of use utilized in the company’s Gen-3 HALO Clarity system. Mark White, CEO of Nexalin Technology, stated, “This method of use patent award marks a major achievement for the company and follows another recent patent covering our core technology. These patents extend through 2040 and are a critical element of our overall strategy, given the mounting clinical data supporting the benefits of our noninvasive, deep frequency brain stimulation technology in the fields of insomnia, depression, and anxiety.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
- Nexalin Technology appoints Hudson to Military & Government Advisory Board
- Nexalin Technology announces results of clinical study on Gen-2 tACS device
- Nexalin Technology commences sales of Gen-2 neurostimulation device
- Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology